|
News FDA Approves Merck’s ISENTRESS (raltegravir) for Use in Children Ages Two Years and Older as Part of HIV-1 Combination Therapy
Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) recently approved the use of ISENTRESS® (raltegravir) in combination with other antiretroviral (ARV) medicines, for the treatment of HIV-1 infection in pediatric patients two years of age and older and weighing at least 10 kg. |
|
News Merck`s ISENTRESS (raltegravir) Demonstrated Durable Reductions in HIV-1 Viral Load and Sustained Tolerability At Three Years of Treatment in Previously Untreated Adult Patients Infected with HIV-1
Merck announced that new Phase III data showed that adult patients with HIV-1 infection maintained undetectable viral loads and increases in CD4 cell counts at three years of treatment with ISENTRESS® (raltegravir) tablets in combination therapy, comparable to treatment with efavirenz in combination therapy. |
|
News Merck Reports Initial Results of Phase III Study of ISENTRESS® (raltegravir) Investigational Once-Daily Dosing in Treatment-Naive Adult Patients Infected with HIV-1
Merck reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naive adult patients infected with HIV-1. |
|
News Merck and The ADAP Crisis Task Force Announce Key Initiatives to Help Provide Funding Relief to AIDS Drug Assistance Programs (ADAPs) across the U.S.
WHITEHOUSE STATION, N.J., May 6, 2010 –Today, Merck & Co., Inc., and the ADAP Crisis Task Force (ACTF) announced a series of key initiatives to help struggling state AIDS Drug Assistance Programs (ADAPs) continue to provide people living with HIV access to medicines. |
|
Leaflet Drug Raltegravir (Oral Route)
Description: Raltegravir is used together with other medicines to treat human immunodeficiency virus (HIV) infection. |
|
Leaflet Drug Isentress
Description: Raltegravir is used together with other medicines to treat human immunodeficiency virus (HIV) infection. |
